RFG Advisory Group LLC Increases Position in Merck & Company, Inc. (MRK)

RFG Advisory Group LLC increased its stake in Merck & Company, Inc. (NYSE:MRK) by 105.6% in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 29,270 shares of the company’s stock after acquiring an additional 15,033 shares during the period. RFG Advisory Group LLC’s holdings in Merck & were worth $1,857,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. Fort Washington Investment Advisors Inc. OH boosted its position in Merck & by 133.4% during the first quarter. Fort Washington Investment Advisors Inc. OH now owns 144,247 shares of the company’s stock valued at $9,165,000 after buying an additional 82,454 shares during the period. Russell Investments Group Ltd. boosted its position in Merck & by 2.6% during the second quarter. Russell Investments Group Ltd. now owns 4,206,648 shares of the company’s stock valued at $269,678,000 after buying an additional 107,201 shares during the period. Meag Munich Ergo Kapitalanlagegesellschaft MBH boosted its position in Merck & by 41.9% during the second quarter. Meag Munich Ergo Kapitalanlagegesellschaft MBH now owns 296,294 shares of the company’s stock valued at $19,028,000 after buying an additional 87,443 shares during the period. Stevens Capital Management LP purchased a new stake in Merck & during the first quarter valued at about $15,126,000. Finally, Trust Co boosted its holdings in shares of Merck & by 2.8% during the first quarter. Trust Co now owns 68,789 shares of the company’s stock worth $4,371,000 after purchasing an additional 1,852 shares during the period. Institutional investors own 73.15% of the company’s stock.

Merck & Company, Inc. (NYSE:MRK) opened at $55.10 on Tuesday. Merck & Company, Inc. has a one year low of $54.41 and a one year high of $66.80. The firm has a market cap of $151,151.77, a P/E ratio of 14.26, a price-to-earnings-growth ratio of 2.39 and a beta of 0.78. The company has a current ratio of 1.43, a quick ratio of 1.16 and a debt-to-equity ratio of 0.57.

Merck & (NYSE:MRK) last announced its earnings results on Friday, October 27th. The company reported $1.11 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.03 by $0.08. Merck & had a net margin of 11.60% and a return on equity of 27.08%. The business had revenue of $10.33 billion during the quarter, compared to the consensus estimate of $10.54 billion. During the same quarter last year, the firm earned $1.07 earnings per share. The business’s revenue for the quarter was down 2.0% on a year-over-year basis. equities research analysts expect that Merck & Company, Inc. will post 3.95 EPS for the current fiscal year.

A number of research firms have recently weighed in on MRK. J P Morgan Chase & Co set a $70.00 target price on shares of Merck & and gave the stock a “buy” rating in a report on Sunday, October 29th. Berenberg Bank reiterated a “hold” rating on shares of Merck & in a report on Wednesday, November 1st. BMO Capital Markets set a $70.00 target price on shares of Merck & and gave the stock a “buy” rating in a report on Wednesday, October 18th. Zacks Investment Research lowered shares of Merck & from a “hold” rating to a “sell” rating in a report on Wednesday, October 11th. Finally, Credit Suisse Group reiterated an “outperform” rating and set a $74.00 target price (down from $75.00) on shares of Merck & in a report on Tuesday, September 5th. Two research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and nine have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $67.07.

In other news, Director Thomas H. Glocer sold 5,000 shares of the stock in a transaction that occurred on Wednesday, November 8th. The shares were sold at an average price of $56.20, for a total transaction of $281,000.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.25% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This piece of content was originally posted by TrueBlueTribune and is the property of of TrueBlueTribune. If you are viewing this piece of content on another website, it was stolen and republished in violation of international copyright and trademark laws. The correct version of this piece of content can be read at https://www.truebluetribune.com/2017/11/14/rfg-advisory-group-llc-increases-position-in-merck-company-inc-mrk.html.

Merck & Company Profile

Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Company, Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & (NYSE:MRK)

Receive News & Ratings for Merck & Company Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Company Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply